AMENDED AND RESTATED MATERIAL TRANSFER AND RESEARCH AGREEMENTMaterial Transfer and Research Agreement • September 29th, 2023 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances) • New York
This Amended and Restated Material Transfer and Research Agreement (“Agreement”) is made as of September 20, 2023 (“Effective Date”), by and between AIM IMMUNOTECH, INC., a Delaware Corporation with a principal place of business located at 2117 SW Highway 484, Ocala, Florida 34473 (“AIM”), and Roswell Park Cancer Institute CORPORATION d/b/a roswell park comprehensive cancer centeR, a New York public benefit corporation with a principal place of business located at Elm and Carlton Streets, Buffalo, NY 14263 (“Institute”). AIM and Institute shall be referred to individually as a “party” and together as the “parties.”
Supplementary Agreement (II)Material Transfer and Research Agreement • August 16th, 2021 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances)
Further and pursuant to the Material Transfer and Research Agreement the Parties agree to extend the duration of the Agreement by a period of twenty-four (24) months until 31 May 2023. All other terms and conditions under the agreement shall remain unchanged.
EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL ANDMaterial Transfer and Research Agreement • August 14th, 2020 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances) • New York
This Material Transfer and Research Agreement (the “Agreement”) is made as of May 15, 2020, (“Effective Date”) by and between AIM ImmunoTech, Inc. (“AIM”), located at 2117 SW Highway 484, Ocala, FL 34473, and University of Rochester (“Rochester”), having a business address at the Office of Research & Project Administration 518 Hylan Building, Box 270140, Rochester, NY 14627. AIM and Rochester shall be referred to individually as a “party” and together as the “parties.”
EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND MATERIAL TRANSFER AND RESEARCH AGREEMENTMaterial Transfer and Research Agreement • March 31st, 2021 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances) • Florida
This Agreement is made as of November 29, 2020 (“Effective Date”) by and between AIM IMMUNOTECH INC. (“AIM”), a corporation incorporated under the laws of Delaware, having an Offices at 2117 SW Hwy 484 Ocala Fl 34473 as the supplier of the experimental drug Ampligen® and Ronald Brus, individually and on behalf of Leyden Laboratories, B.V. (“Leyden Labs”) having an office at Keizersgracht 290A, 1016 EW Amsterdam, The Netherlands, (together referred to as “Companies”). AIM and Leyden Labs shall be referred to individually as a “Party” and together as the “Parties.”
EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. MATERIAL TRANSFER AND RESEARCH AGREEMENTMaterial Transfer and Research Agreement • May 30th, 2023 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances) • New York
This Agreement is made as of May 8, 2023 (“Effective Date”) by and between AIM IMMUNOTECH INC. (“AIM”), a corporation incorporated under the laws of Delaware, having an Offices at 2117 SW Hwy 484 Ocala Fl 34473 as the supplier of the experimental drug Ampligen® and Japanese National Institute of Infectious Disease (“NIID”) with its address at Toyama 1-23-1, Shinjuku-ku Tokyo 162-8640, Japan, (NIID”). AIM and NIID shall be referred to individually as a “Party” and together as the “Parties.”
MATERIAL TRANSFER AND RESEARCH AGREEMENTMaterial Transfer and Research Agreement • April 6th, 2020 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances) • New York
This Material Transfer and Research Agreement (“Agreement”) is made as of March [correct date], 2020 (“Effective Date”) by and between AIM ImmunoTech, Inc. (“AIM”), located at 2117 SW Highway 484, Ocala, FL 34473, USA, and Shenzhen Smoore Technology Limited (“Smoore”), located at Block 16th, Dongcai Industry Park, Gushu Village, Xixiang Town, Bao’an District Shenzhen, People’s Republic of China (“PRC”). AIM and Smoore shall be referred to individually as a “Party” and together as the “Parties”.
EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL ANDMaterial Transfer and Research Agreement • August 14th, 2020 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances) • New York
This Agreement is made as of June 22, 2020 (“Effective Date”) by and between AIM IMMUNOTECH INC. (“AIM”), a corporation incorporated under the laws of Delaware, having an Offices at 2117 SW Hwy 484 Ocala Fl 34473 as the supplier of the experimental drug Ampligen® and a collaborative group consisting of Japanese National Institute of Infectious Disease (“NIID”) with its address at 4-7-1 Gakuen, Musashimurayama-shi, Tokyo, 208-0011 Japan, and Shionogi & Co., Ltd. (including its affiliates, “Shionogi”) with its address at 1-8, Doshomachi 3-chome Chuo-ku, Osaka 541-0045 Japan (together referred to as the “Companies”). AIM, Shionogi and NIID shall be referred to individually as a “Party” and together as the “Parties.”
Exhibit 10.12 MATERIAL TRANSFER AND RESEARCH AGREEMENT THIS AGREEMENT is entered into this 1st day of April 1995, by and between OSIRIS THERAPEUTICS, INC., a corporation having a place of business at 11100. Euclid Avenue, Wearn Building, Fourth Floor,...Material Transfer and Research Agreement • July 17th, 1997 • Osiris Therapeutics Inc
AMENDMENT NO. 1 TOMaterial Transfer and Research Agreement • March 26th, 2020 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances) • New York
This First Amendment to the Material Transfer and Research Agreement (the “Agreement”) dated July 11, 2017, by and between AIM ImmunoTech Inc. (“AIM”), formerly Hemispherx Biopharma, Inc., and ROSWELL PARK CANCER INSTITUTE (“INSTITUTE”), who are each a “Party” and together the “Parties” to the Agreement, is entered into as of March 20, 2020 (the “Amendment No. l Effective Date”).
Supplementary Agreement (II)Material Transfer and Research Agreement • August 16th, 2021 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances)
Further and pursuant to the Material Transfer and Research Agreement the Parties agree to extend the duration of the Agreement by a period of twenty-four (24) months until 31 May 2023. All other terms and conditions under the agreement shall remain unchanged.
